How tumor-derived GABA disables tumor TLSs and drives anti-PD-1 resistance in cancer
Tumor-cell NY-ESO-1 Expression Predicts Poor Response to PD-1/PD-L1 Blockade in NSCLC
Background & rationale NY-ESO-1 is an immunogenic cancer-testis antigen and a therapeutic target for TCR-based strategies. Its value as a baseline biomarker for PD-1/PD-L1 blockade in NSCLC remains poorly defined. Because NY-ESO-1 is biologically relevant only when expressed by tumor epithelial cells, this study focused on CK7+/NY-ESO-1+ tumor cells. Study design Cohort 190 baseline FFPE […]
How ADORA2B drives metastasis in pleomorphic sarcoma — and why it’s a tractable target
High-Dimensional Spatial Profiling of the Tumor Immune Microenvironment (TME) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Predictive Biomarkers of Immunotherapy
HNSCC remains a challenging malignancy, with only a subset of patients benefiting from PD-1/PD-L1 blockade immunotherapy. Despite clinical advances, reliable predictive biomarkers to guide patient selection and improve outcomes are urgently needed. Current strategies often rely on PD-L1 expression or tumor mutational burden, but these lack sufficient specificity and sensitivity. The aim of the study […]
How regorafenib plus avelumab reshapes the immune microenvironment of “cold” soft-tissue sarcomas — and why response stays elusive
Spatial transcriptomics reveal crucial determinants of immune exclusion in non-small cell lung cancer: an analysis of the precision medicine BIP study
Background The tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) plays a pivotal role in determining response to immune checkpoint inhibitors (ICI). Immune contextures within the TME are classified into three main profiles based on CD8+ T-cell (CD8) infiltration: inflamed, excluded, and desert. Inflamed tumors are characterized by CD8 infiltration into tumor nests, reflecting […]
CCR8 positive Tregs and Their Correlation with Immunotherapy Response in Advanced Non-Small Cell Lung Cancer (NSCLC)
The chemokine receptor CCR8 is selectively expressed on activated regulatory T cells (Tregs), which are recognized as potent immunosuppressive modulators within the tumor microenvironment. Several clinical trials are currently evaluating the therapeutic benefit of selectively depleting these cells to enhance the efficacy of immune checkpoint inhibitors (ICIs). However, the prognostic and predictive value of activated […]
Tertiary Lymphoid Structures as Predictors of Immune Checkpoint Inhibitor Efficacy in NSCLC & the Development of an Ex Vivo Model for Precision Medicine
Tertiary lymphoid structures (TLS) emerge as essential players in modulating anti-tumor immune responses and shaping the outcomes of immune checkpoint inhibitor (ICI) therapies. Here we explored, on the one hand, the impact of TLS maturity on clinical outcomes in non-small cell lung cancer (NSCLC), and introduce, on the other hand, a novel ex vivo tool […]
Impact of Immune Contexture on Immunotherapy Response in NSCLC: Insights from Multiplex IHC and Machine Learning-Based Phenotyping
Predicting which NSCLC patients will benefit from immunotherapy requires more than measuring a single biomarker. Our previous work has helped show that key spatial features of the tumor microenvironment—such as mature tertiary lymphoid structures (Nature Cancer, 2021; Cell Reports Medicine, 2025) and macrophage infiltration within the tumor compartment (Journal for ImmunoTherapy of Cancer, 2022)—are closely associated with treatment outcome. Building […]
Regorafenib plus avelumab in advanced neuroendocrine tumors — and the IDO1 biomarker that predicts resistance
